Neorich Biopharma Tech Co Limited (NRBP) AI Stock Analysis

60 Followers

Neorich Biopharma Tech Co Limited

(Other OTC:NRBP)

Select Model

Rating:41Neutral

Price Target:$0.67▼(-22.03% Downside)

Action:upgraded

Date:10/30/26

The overall score is deeply pressured by the company's dire financial state, which shows insolvency, negligible revenue, and massive operating losses. This fundamental weakness is the primary driver of the low score. Technicals offer a slight positive offset as the stock price is above short-term moving averages, but this is contradicted by weak momentum indicators. Valuation is also a significant negative, with a negative P/E ratio underscoring the lack of earnings. The company faces substantial going-concern risk.

Positive Factors

Reduced cash burnThe sharp reduction in operating cash outflow shows some progress in controlling cash consumption, even though operations remain cash negative. If maintained, this improvement could extend liquidity and give the company more time to stabilize its business model.

Negative Factors

Minimal scale and weak profitabilityExtremely low revenue and deeply negative operating results indicate that the core business has not yet demonstrated commercial scale or sustainable unit economics. The negative gross profit further weakens confidence that current operations can support durable earnings without major improvement.

Neorich Biopharma Tech Co Limited (NRBP) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $293.82K
Dividend Yield: ―
Average Volume (3M): 1,650
Price to Earnings (P/E): -0.2
Beta (1Y): 0.75
Revenue Growth: 167846.30%
EPS Growth: -295.83%
Country: US
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Specialty Business Services

Neorich Biopharma Tech Co Limited Business Overview & Revenue Model

Company Description

NeoRich BioPharma Tech Co., Ltd. is an international enterprise dedicated to biomedical R&D, precision medicine, cell & gene therapeutics, modernization of traditional Chinese medicine, anti-tumor formulations, and AI-driven drug development. The com...

Neorich Biopharma Tech Co Limited Financial Statement Overview

Summary

Financial health is critically weak. Revenue is minimal and declining ($2.4M), gross profit is negative, and operating losses are massive (-$290.5M). The balance sheet is insolvent with negative equity of -$2.6B and total assets of only $7.5M against $355.6M in debt. Cash flows are persistently negative, indicating an inability to fund operations or service debt. The large net income figure is a non-operational anomaly and does not reflect sustainable profitability.

Income Statement

15Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative

Neorich Biopharma Tech Co Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

NRBP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADXN	44Neutral	$4.89M	-0.69	-172.76%	―	-45.76%	-3.77%
BJDX	44Neutral	$2.92M	-0.11	-113.80%	―	―	95.46%
NRBP	41Neutral	$296.76K	-0.20	21.06%	―	167846.30%	-295.83%
MSPR	19Underperform	$14	0.00	80.67%	―	―	―

* Healthcare Sector Average

Performance Comparison

NRBP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
NRBP	Neorich Biopharma Tech Co., Limited	0.86	-0.14	-14.20%
ADTX	Aditxt, Inc.	0.04	-915.80	-100.00%
ADXN	Addex Therapeutics Ltd (ADR)	4.06	-4.34	-51.67%
MSPR	Msp Recovery, Inc.	0.01	-0.52	-98.11%
BJDX	Bluejay Diagnostics, Inc.	2.61	-20.27	-88.59%
AKAN	Akanda Corp	1.36	-22.04	-94.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Neorich Biopharma Tech Co Limited AI Stock Analysis